Hanall Biopharma (009420) — Capital Reinvestment Ratio
Latest as of September 2025:
0.45x
Hanall Biopharma (009420) has a Capital Reinvestment Ratio of 0.45x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩7.34 Billion) in capital expenditures (₩3.27 Billion). See 009420 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.45x
Capex / Operating Cash Flow
Operating Cash Flow
₩7.34 Billion
KRW
Capital Expenditures
₩3.27 Billion
KRW
Data as of
Sep 2025
Most recent filing
Hanall Biopharma Capital Reinvestment Ratio (2011–2024)
This chart tracks Hanall Biopharma's Capital Reinvestment Ratio across 10 annual periods.
Annual Capital Reinvestment Ratio for Hanall Biopharma (2011–2024)
Year-by-year Capital Reinvestment Ratio for Hanall Biopharma from 2011 to 2024. For live market cap and broader valuation context, see Hanall Biopharma market capitalisation.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 2.46x | ₩9.36 Billion | ₩23.07 Billion | ▲ +694.3% |
| 2023 | 0.31x | ₩29.64 Billion | ₩9.20 Billion | ▲ +176.3% |
| 2022 | 0.11x | ₩25.20 Billion | ₩2.83 Billion | ▼ -98.0% |
| 2021 | 5.48x | ₩839.87 Million | ₩4.61 Billion | ▲ +98.9% |
| 2020 | 2.76x | ₩929.29 Million | ₩2.56 Billion | ▲ +2561.8% |
| 2019 | 0.10x | ₩20.49 Billion | ₩2.12 Billion | ▲ +152.7% |
| 2017 | 0.04x | ₩42.14 Billion | ₩1.73 Billion | ▼ -96.0% |
| 2016 | 1.02x | ₩3.95 Billion | ₩4.03 Billion | ▲ +2.6% |
| 2012 | 0.99x | ₩2.20 Billion | ₩2.18 Billion | ▲ +1627.8% |
| 2011 | 0.06x | ₩7.41 Billion | ₩426.70 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow